Eli Lilly and Company

What the company does

• Global pharmaceutical company focused on a single business segment: human pharmaceutical products.
• Discovers, develops, manufactures, and markets medicines across multiple therapeutic areas.
• Sells products worldwide through a mix of internal sales teams, distributors, and third-party arrangements; in the U.S., most products are distributed through wholesale distributors.

Global footprint and scale

• Principal domestic and international executive offices in Indianapolis, Indiana.
• Major production sites in Indiana, North Carolina, Puerto Rico, and Wisconsin, with additional manufacturing in Europe and Asia (examples: Ireland, France, Spain, Italy, China, Japan).
• Research and development facilities primarily in the U.S. (owned facilities in Indiana; leased facilities in California, Massachusetts, Colorado, and New York).
• Products sold in roughly 90 countries; uses LillyDirect (direct-to-patient platform) where applicable outside the U.S.

Workforce

• Approximately 50,000 employees at the end of 2025.
• About 27,000 employees located outside the U.S.
• Approximately 12,000 employees engaged in research and development.

Product portfolio highlights

Therapeutic areas and representative products:

• Cardiometabolic Health

  • Basaglar (insulin analog) in collaboration with Boehringer Ingelheim.
  • Humalog and related insulin products (Humalog U-100, U-200, Mix varieties, lispro products).
  • Jardiance (empagliflozin) in collaboration with Boehringer Ingelheim — for type 2 diabetes and to reduce cardiovascular death and related risks.
  • Mounjaro (tirzepatide) receptor agonist — for adults with type 2 diabetes; marketed as Mounjaro in many markets.
  • Trulicity (dulaglutide) — for adults and pediatric patients (10+) with type 2 diabetes; cardiovascular risk reduction in defined populations.
  • Zepbound — for obesity/overweight with weight-related comorbidities, with market-specific guidance outside the U.S.

• Oncology

  • Cyramza — second-line treatment options for several cancers including gastric/GEJ, NSCLC, colorectal cancer, and hepatocellular carcinoma.
  • Jaypirca — treatment for CLL/SLL, MCL, and RET-rearranged NSCLC in adults.
  • Retevmo — RET gene fusion–targeted therapy for thyroid and other solid tumors in adults and children.
  • Verzenio — HR+, HER2- metastatic breast cancer; also used with endocrine therapy for early breast cancer at high risk of recurrence.
  • Inluriyo — for ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer; additional hematology and RET-fusion indications in specific markets.
  • Additional oncology products supporting first- and later-line indications across tumor types.

• Immunology

  • Ebglyss — atopic dermatitis and other inflammatory conditions (in Europe, in collaboration with Almirall).
  • Olumiant (baricitinib) — rheumatoid arthritis and other indications.
  • Omvoh — ulcerative colitis and Crohn’s disease in adults; plaque psoriasis and related conditions.
  • Taltz (ixekizumab) — plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.

• Neuroscience

  • Emgality — migraine prevention and episodic cluster headache treatment.
  • Kisunla — for early symptomatic Alzheimer’s disease with amyloid pathology and related cognitive impairment contexts.

• Additional products and support

  • Delivery devices, direct-to-patient services (LillyDirect), and access programs to support patient access and product delivery.

Revenue context and scale

• Six products each generated more than $3 billion in direct product and/or collaboration and other revenues in 2025.
• Those six products (Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, Jardiance — including associated products Glyxambi, Synjardy, and Trijardy XR) collectively accounted for 82% of Lilly’s total revenues in 2025.

Marketing, distribution, and access

• Global sales through internal teams, distributors, third parties, and LillyDirect where applicable.
• In the U.S., sales flow primarily through wholesale distributors; three wholesalers (McKesson, Cencora, Cardinal Health) accounted for a substantial share of revenue in 2025.
• Employs direct-to-provider and consumer-focused activities, disease-state information, digital channels, partnerships, and payer arrangements including risk-sharing and rebates.

Intellectual property and regulatory environment

• Holds and licenses numerous patents and uses data protection and term-extension mechanisms to manage market exclusivity.
• Data protection and extension opportunities vary by jurisdiction (U.S., Europe, Japan) and by product type (small molecule versus biologics).
• Operates through collaborations and licenses across regions and manages intellectual property challenges, regulatory trial requirements, and biosimilar competition risk.

Manufacturing and supply chain

• Active ingredient manufacturing and product finishing occur at company facilities and with third-party providers.
• Expansion underway with new sites in multiple U.S. states and in Europe.
• Global supply chain includes reliance on China-based suppliers for portions of the supply chain.
• Emphasizes quality systems and manages exposure to supply disruptions, pricing pressures, and demand variability.

People, governance, and risk management

• Emphasizes human capital values such as integrity, excellence, and respect for people, with ongoing investments in training and development.
• Cybersecurity program aligned with industry standards; governance includes board oversight and dedicated information security leadership.
• Maintains comprehensive regulatory compliance activities and manages risks related to regulatory changes, pricing and reimbursement, and litigation exposure.